Skip to content
Catalyst

PapersPMID:27851868

Pharmacotherapies for sleep disturbances in dementia.

The Cochrane database of systematic reviews2016The record ↗

  1. Finding, very limited evidenceno difference foundActivities of daily living score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “From two studies, we found no effect of melatonin on cognition or performance of activities of daily living (ADL).”
    Study
    meta-analysis
    Population
    patients with moderate-to-severe Alzheimer's disease dementia and an identified sleep disturbance, melatonin doses up to 10 mg; no specific ADL instrument named

Study record

Design
meta-analysis
Species
human
Population
adults with dementia (mostly Alzheimer's disease) with an identified sleep disturbance; 222 participants across four melatonin studies (two yielded meta-analysable data)
Participants
222
Comparator
placebo
Duration
not reported
Endpoints measured
5